Board of Directors
Bruce Booth DPhil - Chairman
Bruce Booth is a partner at Atlas Venture and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce is currently chairman of AvroBio, miRagen Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapetics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB, Shire, Pfizer, and Takeda. He also serves on the board of the National Venture Capital Association. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Geoff is an experienced CEO with proven success leading innovative businesses. While CEO of Organogenesis Inc., the company treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalled position within regenerative medicine. Geoff was founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts. Through his public and private enterprise work, Geoff is dedicated to applying innovation to reshape and improve the quality of healthcare.
Christopher Paige PhD, FCAHS
Christopher earned a PhD in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Dr Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1997, he returned to OCI, now part of the University Health Network, to assume the role of Vice President, Research at UHN. Dr Paige is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.
Scott Requadt JD, MBA
Scott Requadt, JD, MBA, is currently a Managing Director for Clarus. Scott has 15+ years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company’s intellectual property group. Prior to TransForm, Scott practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance)from McGill University (First Class Honors), a J.D. from University of Toronto and most recently an MBA from Harvard Business School, where he was a Baker Scholar. Mr. Requadt has been involved in multiple Clarus investments spanning both therapeutics and medtech. More recently, he led Clarus’ investments in a royalty interest in ibrutinib and in the IPO of Intercept Pharmaceuticals (NASDAQ:ICPT), and has been involved in several structured R&D risk-sharing investments with large pharma partners.
Joshua Resnick MD, MBA
Dr. Resnick is a highly-regarded life sciences leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization. Before joining SVLS, Dr. Resnick was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co. Prior to MRL Ventures, Dr. Resnick was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Dr. Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, Dr. Resnick was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. Dr. Resnick is also an Attending Physician at Massachusetts General Hospital as well as Brigham and Women’s Hospital, and an Instructor in Medicine at Harvard Medical School. Dr. Resnick graduated Magna Cum Laude from Williams College and received his MD and MBA from the University of Pennsylvania School of Medicine and Wharton School of Business.